Uveal Melanoma With Liver Metastases
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Interleukin2
Research Leaders
5 sponsors active, led by Mirati Therapeutics Inc.
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
Research Network
Common Treatments
- Interleukin21
- Tislelizumab1
- Autologous Tumor Infiltrating Lymphocytes1
- Melphalan1
Active Sponsors
- Mirati Therapeutics Inc.1
- Grupo Español Multidisciplinar de Melanoma1
- Miltenyi Biomedicine GmbH1
- Vastra Gotaland Region1
- BeiGene1
Top Investigators
Department of Oncology, Sahlgrenska University Hospital, Sweden
ICO L´Hospitalet
Related Conditions
- Metastases To Liver1
- Skin Melanomas1
- Ocular Melanomas1
- Metastatic Cutaneous Melanoma1
- Metastatic Uveal Melanoma1